A previously conducted phase Ib study on a small number of overall 69 AML patients showed an improvement in CR rates in FLT3-ITD-mutated AML when midostaurin was added to standard chemotherapy, indicating promising therapeutic effects of TKI [82]. This evidence concerns the gene FLT3 and acute myeloid leukemia.